What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?
نویسنده
چکیده
Anti-vascular endothelial growth factor (VEGF) therapy has revolutionised the treatment of retinal disease, and appears to be very safe. Nevertheless, there are several lines of evidence that imply that small doses of these agents could potentially have a systemic effect. The clinical significance of these systemic effects remains unclear, but further study is indicated.
منابع مشابه
Evaluation of the Vascular Density, the Area of Foveal Avascular Zone, and Corrected Vision in Patients with Diabetic Macular Edema after Anti-VEGF Therapy
Background and Objective: This study aimed to evaluate the changes in macular superficial and deep capillary plexus (SCP and DCP) density, Foveal Avascular Zone (FAZ) area, and visual acuity in patients with diabetic macular edema after anti-VEGF therapy. Materials and Methods: This descriptive-analytical study utilized before and after treatment design. In total, 30 eyes of 30 patients with d...
متن کاملSystemic and kidney toxicity of intraocular administration of vascular endothelial growth factor inhibitors.
Intravenous injection of angiogenesis-inhibitor drugs is used widely to treat cancers. Associated renal complications primarily involve proteinuria and hypertension, and thrombotic microangiopathies also have been described. Intravitreal anti-vascular endothelial growth factor (VEGF) therapy currently is used by ophthalmologists to treat neovascularization in age-related macular degeneration. H...
متن کاملEffect of Avastin on intraocular pressure before and after intravitreal injections
Introduction: Intravitreal Avastin (bevacizumab) injection is reportedly accompanied by ocular and systemic side-effects. Our enquiry assesses whether there are any differences between intraocular pressure (IOP) in baseline and on the day after injection in patients treated for retinal disease. Methods: In this experimental study, 82 eyes with retinal diseases that had indication for anti-VEGF...
متن کاملAnti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy
Retinopathy of prematurity (ROP) remains a leading cause of childhood blindness, affecting infants born prematurely. ROP is characterized by the onset of delayed physiological retinal vascular development (PRVD) and followed by pathologic neovascularization into the vitreous instead of the retina, called intravitreal neovascularization (IVNV). Therefore, the therapeutic strategy for treating RO...
متن کاملVascular endothelial growth factor inhibition in uveitis: a systematic review.
Vascular endothelial growth factor (VEGF) plays an important role in the pathogenesis of uveitic complications such as cystoid macular oedema (CMO), choroidal neovasularisation (CNV) and retinal neovascularisation (RNV). The use of intravitreal anti-VEGF therapies, namely bevacizumab and ranibizumab, has recently been described in the treatment of these complications. Evidence describing the us...
متن کامل